Back to Search
Start Over
High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy.
- Source :
-
PloS one [PLoS One] 2020 Dec 28; Vol. 15 (12), pp. e0244131. Date of Electronic Publication: 2020 Dec 28 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- Introduction: A large proportion of patients with COVID-19 develop acute kidney injury (AKI). While the most severe of these cases require renal replacement therapy (RRT), little is known about their clinical course.<br />Methods: We describe the clinical characteristics of COVID-19 patients in the ICU with AKI requiring RRT at an academic medical center in New York City and followed patients for outcomes of death and renal recovery using time-to-event analyses.<br />Results: Our cohort of 115 patients represented 23% of all ICU admissions at our center, with a peak prevalence of 29%. Patients were followed for a median of 29 days (2542 total patient-RRT-days; median 54 days for survivors). Mechanical ventilation and vasopressor use were common (99% and 84%, respectively), and the median Sequential Organ Function Assessment (SOFA) score was 14. By the end of follow-up 51% died, 41% recovered kidney function (84% of survivors), and 8% still needed RRT (survival probability at 60 days: 0.46 [95% CI: 0.36-0.56])). In an adjusted Cox model, coronary artery disease and chronic obstructive pulmonary disease were associated with increased mortality (HRs: 3.99 [95% CI 1.46-10.90] and 3.10 [95% CI 1.25-7.66]) as were angiotensin-converting-enzyme inhibitors (HR 2.33 [95% CI 1.21-4.47]) and a SOFA score >15 (HR 3.46 [95% CI 1.65-7.25).<br />Conclusions and Relevance: Our analysis demonstrates the high prevalence of AKI requiring RRT among critically ill patients with COVID-19 and is associated with a high mortality, however, the rate of renal recovery is high among survivors and should inform shared-decision making.<br />Competing Interests: The authors declare that they have no financial conflicts of interest to disclose. MRO and MJC are both investigators for Remdesivir (sponsored by Gilead) and convalescent plasma (sponsored by Amazon). This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Subjects :
- Acute Kidney Injury virology
Aged
Critical Illness mortality
Female
Humans
Intensive Care Units
Kidney virology
Male
Middle Aged
New York City
Proportional Hazards Models
Renal Replacement Therapy methods
Retrospective Studies
SARS-CoV-2 pathogenicity
Survivors
Acute Kidney Injury etiology
Acute Kidney Injury pathology
COVID-19 complications
Kidney pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 15
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 33370368
- Full Text :
- https://doi.org/10.1371/journal.pone.0244131